We are live on ! Find out more
IMUX icon

Immunic

54 hedge funds and large institutions have $2.39M invested in Immunic in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 7

0.03% less ownership

Funds ownership: 0.08%0.05% (-0.03%)

13% less funds holding

Funds holding: 6254 (-8)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

88% less call options, than puts

Call options by funds: $76K | Put options by funds: $659K

97% less capital invested

Capital invested by funds: $95M → $2.39M (-$92.6M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
54
Holders Change
-8
Holders Change %
-12.9%
% of All Funds
1.23%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
15
Increased
20
Reduced
7
Closed
23
Calls
$76K
Puts
$659K
Net Calls
-$583K
Net Calls Change
+$1.95M

IMUX Hedge Fund Activity: Q3 2018 in Review

54 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q3 2018, worth a combined $2.39M — down 97% from $95M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of IMUX and 15 opened new positions — a net loss of 8 holders — while 7 trimmed existing stakes and 20 added.

The largest buyer was Millennium Management, adding an estimated $5.12M. The largest seller was Victory Capital Management, exiting entirely with an estimated $21.1M sold.

  • 54 institutional investors held Immunic (IMUX) as of Q3 2018, down from 62 in Q2 2018.
  • Funds reported $2.39M of Immunic stock for Q3 2018, down 97% quarter-over-quarter.
  • 15 funds opened new Immunic positions in Q3 2018 and 23 closed out, a net change of -8 holders.
  • The largest Immunic buyer in Q3 2018 was Millennium Management, an estimated $5.12M added.
  • The largest Immunic seller in Q3 2018 was Victory Capital Management, an estimated $21.1M sold.

Based on aggregated 13F filings for Q3 2018.